Volatility and Risk
Pieris Pharmaceuticals has a beta of 0.66, indicating that its stock price is 34% less volatile than the S&P 500. Comparatively, Evelo Biosciences has a beta of 1.29, indicating that its stock price is 29% more volatile than the S&P 500.
Institutional & Insider Ownership
40.1% of Pieris Pharmaceuticals shares are held by institutional investors. Comparatively, 0.3% of Evelo Biosciences shares are held by institutional investors. 6.4% of Pieris Pharmaceuticals shares are held by company insiders. Comparatively, 1.0% of Evelo Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Earnings and Valuation
This table compares Pieris Pharmaceuticals and Evelo Biosciences”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Pieris Pharmaceuticals | $42.81 million | 0.49 | -$24.54 million | ($12.10) | -1.32 |
| Evelo Biosciences | N/A | N/A | -$114.53 million | ($13.29) | 0.00 |
Profitability
This table compares Pieris Pharmaceuticals and Evelo Biosciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Pieris Pharmaceuticals | -39.71% | -75.34% | -54.49% |
| Evelo Biosciences | N/A | N/A | N/A |
Summary
Pieris Pharmaceuticals beats Evelo Biosciences on 5 of the 9 factors compared between the two stocks.
About Pieris Pharmaceuticals
Pieris Pharmaceuticals, Inc., a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc.; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies. The company was founded in 2001 and is headquartered in Boston, Massachusetts.
About Evelo Biosciences
Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
